CDEK by Data4ThePeople
Sign in Sign up
← All drugs Report issue

reparixin

Small moleculeexperimental

Clinical trial activity

15 trials · 21 clinical orgs · 0 marketing orgs

Phase 1
1
Phase 2
12
Phase 3
5
Phase 4
0

Earliest trial started May 1, 2005 (NCT00224406)

Timeline

2000s

  1. Jan 1, 2005

    Earliest Phase 2 Sponsor(trial)

2010s

  1. Jan 1, 2012

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2012

    Earliest Phase 3 Sponsor(trial)

Indications

Studied for

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

CC(C)Cc1ccc([C@@H](C)C(=O)NS(C)(=O)=O)cc1
Mol. weight
283.39 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Single Stereoisomer
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • 2-(4-isobutylphenyl)propionylmethanesulfonamide
  • df-1681y
  • df-1681y
  • (r)-2-(4-isobutylphenyl)propionylmethanesulfonamide
  • reparixin
  • reparixin
  • reparixin
  • reparixin
  • reparixin
  • repertaxin
  • repertaxin
  • repertaxin

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT05835466Phase 2Jun 27, 2023Dompe Pharmaceuticals, Icahn School of Medicine at Mount Sinai, University of Rochester
NCT05496868Phase 2Jan 31, 2023Dompe Pharmaceuticals
NCT05212701Phase 2Apr 19, 2022Dompe Pharmaceuticals
NCT05254990Phase 3Apr 6, 2022Dompe Pharmaceuticals
NCT04878055Phase 3Feb 14, 2021Dompe Pharmaceuticals, IRCCS Ospedale San Raffaele Centro di Ricerca Anestesia e Rianimazione
NCT04794803Phase 2/Phase 3 (Phase 3)May 5, 2020Dompe Pharmaceuticals, Vita-Salute University of Milano. Italy
NCT02370238Phase 2Jun 1, 2015Dompe Pharmaceuticals, Pharmaceutical Research Associates, Inc. (PRA)
NCT03031470Phase 2Mar 1, 2015Dompe Pharmaceuticals, Government of Russia
NCT01967888Phase 2/Phase 3 (Phase 3)Feb 1, 2014Dompe Pharmaceuticals, University of Minnesota
NCT01861054Phase 2Feb 1, 2013Dompe Pharmaceuticals
NCT01817959Phase 3Oct 1, 2012Dompe Pharmaceuticals, Karolinska Institute, Lund University, Newcastle University, University of Chicago, University of Gothenburg, University of Milan, Uppsala University, Vita-Salute University of Milano. Italy
NCT02001974Phase 1Jan 1, 2012Dompe Pharmaceuticals, Pharmaceutical Research Associates, Inc. (PRA), Pinnacle Research Group, Temple University, Thomas Jefferson University, University of Kansas, University of Michigan
NCT01220856Phase 2Jul 1, 2010Dompe Pharmaceuticals, Technical University of Dresden, Vita-Salute University of Milano. Italy
NCT00248040Phase 2Oct 1, 2005Dompe Pharmaceuticals
NCT00224406Phase 2May 1, 2005Dompe Pharmaceuticals
Showing 15 of 15 trials
Page 1 / 1

Organizations

Research & Development (21)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Dompe PharmaceuticalsFor profit151432005
Vita-Salute University of Milano. ItalyAcademic/Hospital3022010
Pharmaceutical Research Associates, Inc. (PRA)For profit2022012
Government of RussiaGovernment1012015
Icahn School of Medicine at Mount SinaiAcademic/Hospital1112023
IRCCS Ospedale San Raffaele Centro di Ricerca Anestesia e RianimazioneAcademic/Hospital1012021
Karolinska InstituteAcademic/Hospital1012012
Lund UniversityAcademic/Hospital1012012
Newcastle UniversityAcademic/Hospital1012012
Pinnacle Research GroupFor profit1012012
Technical University of DresdenAcademic/Hospital1012010
Temple UniversityAcademic/Hospital1012012
Thomas Jefferson UniversityAcademic/Hospital1012012
University of ChicagoAcademic/Hospital1012012
University of GothenburgAcademic/Hospital1012012
University of KansasAcademic/Hospital1012012
University of MichiganAcademic/Hospital1012012
University of MilanAcademic/Hospital1012012
University of MinnesotaAcademic/Hospital1012014
University of RochesterAcademic/Hospital1012023
21 organizations
Page 1 / 2